GET DAILY SIGNALSPalisade Bio (PALI) Stock Declines -24% Over 30 Days as Clinical and Market Factors Weigh
Key Takeaways
- PALI shares declined roughly 24% over the trailing 30 days, falling from a closing price of $1.48 on October 14, 2026, to $1.12 on November 13, 2026.
- The decline extends a longer multi-month downtrend, with the stock down close to 48% over the most recent quarter.
- Third-quarter results released in early November showed a wider net loss and a modest per-share miss, refocusing attention on rising research spending and share dilution.
- The core investment thesis remains PALI-2108, an oral PDE4 inhibitor prodrug in Phase 2 development for ulcerative colitis and Crohn's disease.
- Broad risk-off sentiment in small-cap biotech, compounded by elevated Treasury yields, amplified stock-specific weakness.
- Analyst price targets were reduced after earnings, even as several firms maintained their ratings.
Palisade Bio (PALI) Company Overview and Market Position
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company headquartered in Denver, Colorado, focused on developing oral phosphodiesterase-4 (PDE4) inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon. Its lead candidate, PALI, is being developed for inflammatory bowel disease (IBD), including moderately to severely active ulcerative colitis and Crohn's disease.
The company is pre-revenue, generating minimal or no recurring sales, and its investment case is driven almost entirely by clinical progress. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. PALI-2108's mechanism is aimed at delivering anti-inflammatory activity directly at the site of disease while potentially limiting the systemic side effects associated with existing IBD therapies. With no approved products on the market, Palisade Bio's valuation depends on successful execution of its Phase 2 programs and the eventual generation of positive efficacy data.
Palisade Bio (PALI) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, PALI shares moved from a closing price of $1.48 on October 14, 2026, to $1.12 on November 13, 2026, a decline of approximately 24%. The move was characterized by a steady grind lower punctuated by sharp single-day selling, with the stock trading near the low end of its 52-week range during the period.
The picture is more pronounced over the last quarter. From a closing price of $2.15 on August 13, 2026, shares fell to $1.12 by November 13, 2026, a decline of roughly 48%. This reflects a sustained downward trend rather than an isolated event, as the company transitioned from Phase 1 data into larger, more expensive Phase 2 trials against a backdrop of weakening risk appetite for speculative biotech names.
What Drove PALI Stock Price in the Last 30 Days
Several factors contributed to the stock's decline over the trailing 30 days. The most significant catalyst was the release of third-quarter 2026 financial results on November 10, 2026. Palisade Bio reported a net loss of approximately $14.6 million, or $0.07 per share, a penny below consensus estimates. Operating expenses rose sharply year over year as the company ramped up spending on PALI-2108 clinical development, and the release highlighted continued cash burn alongside the absence of meaningful revenue.
Analyst actions followed the report. Piper Sandler lowered its price target on Palisade Bio to $16 from $25 while maintaining an Overweight rating, and H.C. Wainwright lowered its target to $5 from $7 while keeping a Buy rating. These revisions, while retaining positive ratings, reflected recalibrated expectations and contributed to selling pressure.
On the clinical front, the company announced progress that was not enough to offset negative sentiment. The first patient was dosed in the global Phase 2b ASCENTRA-UC trial on October 27, 2026, and the FDA had previously cleared the IND for the Phase 2a ASCENTRA-CD study. However, these milestones underscored that the next meaningful efficacy readouts remain roughly a year or more away. Broader market conditions also weighed on the stock, as elevated Treasury yields and a risk-off tone pressured small-cap and pre-revenue biotechnology names across the sector.
What Drove PALI Stock Performance Over the Last Quarter
The roughly 48% decline over the last quarter reflects a convergence of company-specific and macro factors. Over the three-month period, Palisade Bio advanced PALI-2108 from late-stage Phase 1 evaluation into two concurrent Phase 2 trials, a transition that meaningfully increased operating expenses and cash burn. Third-quarter research and development expense climbed to roughly $10.6 million from about $1.4 million a year earlier.
Investor concerns about dilution also persisted. The company's share count has expanded substantially through prior financings, and a shelf registration filing for additional stock has kept future capital-raising overhang in view. A previously disclosed material weakness in internal control over financial reporting remained unremediated as of September 30, 2026. These factors, combined with a broader rotation away from speculative biotech amid higher interest rates, created sustained downward pressure on the shares throughout the quarter.
PALI Stock Forecast Drivers: What Investors Should Watch Next
The primary catalysts for Palisade Bio remain clinical. Investors will focus on enrollment progress and interim updates from the Phase 2b ASCENTRA-UC trial in ulcerative colitis, with topline induction results targeted for the fourth quarter of 2027. The Phase 2a ASCENTRA-CD trial in Crohn's disease is expected to begin enrollment in the first quarter of 2027, with a primary efficacy readout targeted for the first quarter of 2028.
On the financial side, the company reported approximately $113.6 million in cash and equivalents as of September 30, 2026, which management has stated is sufficient to fund operations through those key readouts. However, rising clinical spending, the potential for additional financing, and continued share dilution remain important considerations. Macroeconomic conditions, particularly interest-rate trends that influence appetite for pre-revenue biotech, and the competitive IBD treatment landscape will also shape the stock's trajectory. These factors should be monitored alongside any future analyst revisions and regulatory developments.
Exploring Automated Trading Strategies
In my own analysis, I often review Tickeron’s Trending AI Robots to see how different automated strategies are performing across market conditions. The page highlights top bots with varied approaches, from short-term momentum to longer-term trends, helping identify active signals that align with current environments. This resource offers a practical way to compare systematic options without replacing core research.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
Momentum Indicator for PALI turns negative, indicating new downward trend
PALI saw its Momentum Indicator move below the 0 level on October 16, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 95 similar instances where the indicator turned negative. In 90 of the 95 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PALI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for PALI entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PALI's RSI Indicator exited the oversold zone, 34 of 38 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for PALI just turned positive on November 04, 2026. Looking at past instances where PALI's MACD turned positive, the stock continued to rise in 33 of 41 cases over the following month. The odds of a continued upward trend are 80%.
Following a +11.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where PALI advanced for three days, in 168 of 198 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
PALI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.618) is normal, around the industry mean (3.498). P/E Ratio (1.738) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (526.316) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. PALI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PALI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company, which engages in the research, development, and commercialization of central nervous system therapies based on human neuronal stem cells and small molecule compounds
Industry Biotechnology
Advertisement